Global Clinical Trials in 2026: The Key Challenges Sponsors Need to Prepare For in 2026

If you've spent any time in a trial steering committee meeting this year, you already know the mood has shifted. Clinical development remains vibrant, particularly in oncology, rare diseases, and biologics, with the global trials market expected to exceed $200 billion in the coming decade. However, the simultaneous growth and complexity have rendered traditional operational strategies inadequate for the current landscape.

In early 2026, sponsors of multi-region programs face execution challenges rather than difficulties in finding good science. Key issues include maintaining consistency, compliance, and budget adherence, particularly as operational landscapes have shifted significantly in five years. Clinical operations leads discuss these ongoing challenges and the practical adaptations sponsors are implementing to address them.

Sponsors’ interest shifted to the Asia Pacific region

Global trials are shifting from a focus on North America and Western Europe to include substantial contributions from the Asia-Pacific region, particularly China, which has shown significant year-over-year growth in new trial starts. Additionally, countries like India, Brazil, and Colombia are emerging as important destinations for trials, fuelled by large, treatment-naive patient populations and developing research infrastructures.

Expanding recruitment to new countries complicates operations due to varying regulatory pathways, ethical committee norms, import/export rules, and site capabilities. A protocol developed in one location may not easily apply elsewhere, and sponsors who attempt to duplicate protocols without adaptation may incur higher query volumes and amendment cycles.

To resolve the above non-compliance, regional partners are becoming increasingly important for sponsors, as they not only navigate regulatory paperwork but also facilitate relationships with local ethics boards and site investigators. Trials experience quicker transitions from protocol to first-patient-in when local experts interpret global objectives for effective local execution, preventing issues from arising later.

Complexity in protocol development and burden on site personnel

Phase III protocols have increased significantly in complexity due to more procedural requirements and data collection, including additional amendments, endpoints, and assessments per visit. While each modification may be justified separately—a biomarker sub-study here, a caregiver-burden measure there, and a digital or wearable-based exploratory endpoint layered on top. During a patient visit, individuals at the site level experience the cumulative weight of all factors rather than individual components.

This is where a lot of well-designed trials quietly stall. Site staff turnover is increasing, visit windows are being missed, and data quality issues are emerging due to the operational load exceeding the capacity of a typical site team.

The sponsors are managing this well by proactively pressure-testing protocols from the coordinator chair prior to finalization and investing in eCOA and rater training designed to alleviate rather than just digitize existing burdens. If a digital measure demands more effort from an overburdened site coordinator than its paper counterpart, it cannot be considered an improvement.

Decentralized clinical trials and hybrid models are evolving unevenly.

Decentralized clinical trials (DCTs) have become a standard design in global protocols, significantly improving patient access, particularly in studies related to rare diseases and chronic conditions, where recruitment has often been hindered by travel burdens.

The current challenge in DCTs lies in implementing solutions without adding further operational complexities. Essential technologies like wearables, ePRO apps, telehealth, and local labs must communicate effectively with the core electronic data capture (EDC) system. Persistent interoperability gaps lead to increased reconciliation tasks and data queries, negating the intended benefits of DCTs.

In hybrid models, sponsors achieve better value by standardizing their technology stack across studies, rather than allowing each protocol to choose its own vendors. This approach minimizes site burden at scale, despite being less glamorous than adopting cutting-edge sensor platforms.

AI Adoption Has Moved From Pilot to Expectation

AI-assisted protocol design, risk-based monitoring, automated query resolution, and predictive site performance modeling have transitioned from being innovative showcases to standard components in trial budgets. Their implementation has led to significant decreases in manual data cleaning and expedited site feasibility assessments, demonstrating tangible efficiency gains for sponsors.

The shift towards AI-driven decisions is under scrutiny from regulators, with expectations for validation, transparency, and human oversight varying by region. An acceptable risk-based monitoring algorithm in one area may require more documentation or a different validation for another. Sponsors integrating AI tools without adequate governance and audit trails risk facing inspections that negate efficiency gains.

Sponsors rethinking their position in the actual trial

Recent trends indicate that sponsors are increasingly open to changing CRO partners during ongoing programs and are also considering in-housing functions instead of outsourcing entire projects. This shift is driven by the search for improved value in a cost-sensitive market and the operational ease afforded by the transition to SaaS-based platforms over traditional, complex systems.

This situation presents mixed blessings. It empowers sponsors to demand improved performance from partners; switching vendors such as CROs, EDC systems, or central labs incurs high operational costs that are often underestimated. These include the need for site retraining, risks associated with data migration, and a potential gap in institutional knowledge regarding a trial's unique aspects. Effective sponsors approach partner selection as a strategic long-term decision and explicitly include switching costs in vendor contracts and timelines to avoid issues during trials.

Perspective shift of sponsor towards enrolment of patients

Concentrating enrollment at a few high-performing sites has been an efficient short-term strategy, but it limits the diversity of the patient population in clinical trials, which is increasingly important for regulators and payers assessing the generalizability and real-world relevance of trial results.

The 2026 sponsors are proactively integrating community site partnerships and point-of-care research into their site selection strategies, rather than addressing diverse recruitment only when enrollment issues arise. Although this approach incurs higher initial costs for feasibility work, it proves beneficial in terms of sustained enrollment and providing robust data that withstands regulatory scrutiny.

None of these challenges are really new categories—global expansion, protocol complexity, decentralization, AI, vendor strategy, and access have been longstanding concerns in the industry. The key change is that these challenges are now compounding simultaneously across nearly all large programs, rather than appearing as isolated risks.

In 2026, sponsors will gain a competitive advantage not through innovative tools or flashy AI pilots, but by developing operational systems capable of adapting to regulatory changes, site burdens, and technology shifts without complete redesigns. Operational resilience is thus becoming the key factor in success, surpassing individual trial design choices.

How Zenovel is helping sponsors navigate these challenges

Even as sponsors take more ownership of their trial strategy, the reality is that navigating this level of complexity alone is nearly impossible. What most programs need is a service partner capable of managing these challenges efficiently, relentlessly, and at scale, and this is where Zenovel has built its reputation among sponsors as a dependable partner for even the most demanding trials.

Our team brings more than decades of combined on-site and off-site experience across the clinical development lifecycle. From GxP compliance and regulatory strategy to hands-on support through the drug discovery process, we work as an extension of the sponsor's own team rather than a distant vendor. With established partners across Southeast Asia, Europe, the USA, and the UAE, we help sponsors move from protocol to first-patient-in faster, without compromising on quality, compliance, or site relationships along the way.

At Zenovel, we don't just support trials; we help sponsors build the operational resilience needed to run them successfully in a landscape that keeps changing.